GlassScriptPhysician profile
Brian P Levy
NPI 1033186473
$8,141.75
in general payments reported to CMS, 2019-2025
27 companies · $489 in 2025
The $489 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,342 · 2020: $1,100 · 2021: $818 · 2022: $1,394 · 2023: $934 · 2024: $1,065 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,365 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,365.38 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $122.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,476.93 | 2019-2025 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $1,337.87 | 2019-2025 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $825.28 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Amgen INC. | $679.00 | 2019-2023 | |
| Abbvie INC. | $665.80 | 2019-2022 | |
| Amarin Pharma, INC. | $542.82 | 2019-2022 | |
| Esperion Therapeutics, INC. | $249.66 | 2021 | |
| Allergan, INC. | $215.30 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $191.22 | 2022-2024 | Evkeeza |
| Pfizer INC. | $182.59 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $161.04 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $126.30 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $125.11 | 2019 | |
| Sanofi-Aventis U.S. LLC | $124.99 | 2019 | |
| Corcept Therapeutics | $124.37 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $123.13 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $123.11 | 2019 | |
| Medicure Pharma INC. | $122.34 | 2024 | Zypitamag |
| Acadia Pharmaceuticals INC | $121.00 | 2021 | |
| Antares Pharma, INC. | $117.59 | 2023 | Tlando, Xyosted |
| Rhythm Pharmaceuticals, INC. | $114.59 | 2023 | Imcivree |
| Astellas Pharma US INC | $114.59 | 2024 | Veozah |
| Althera Pharmaceuticals LLC | $105.00 | 2022 | |
| Lilly USA, LLC | $91.37 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $54.28 | 2019 | |
| Medtronic, INC. | $15.92 | 2023 | Intellis Adaptivestim |
| Corium, LLC | $10.55 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.